1. Home
  2. PWP vs AKBA Comparison

PWP vs AKBA Comparison

Compare PWP & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PWP
  • AKBA
  • Stock Information
  • Founded
  • PWP 2006
  • AKBA 2007
  • Country
  • PWP United States
  • AKBA United States
  • Employees
  • PWP N/A
  • AKBA N/A
  • Industry
  • PWP Finance: Consumer Services
  • AKBA Biotechnology: Pharmaceutical Preparations
  • Sector
  • PWP Finance
  • AKBA Health Care
  • Exchange
  • PWP Nasdaq
  • AKBA Nasdaq
  • Market Cap
  • PWP 1.1B
  • AKBA 958.6M
  • IPO Year
  • PWP N/A
  • AKBA 2014
  • Fundamental
  • Price
  • PWP $20.64
  • AKBA $3.62
  • Analyst Decision
  • PWP Hold
  • AKBA Strong Buy
  • Analyst Count
  • PWP 3
  • AKBA 5
  • Target Price
  • PWP $23.00
  • AKBA $6.90
  • AVG Volume (30 Days)
  • PWP 1.2M
  • AKBA 5.6M
  • Earning Date
  • PWP 08-01-2025
  • AKBA 08-07-2025
  • Dividend Yield
  • PWP 1.37%
  • AKBA N/A
  • EPS Growth
  • PWP N/A
  • AKBA N/A
  • EPS
  • PWP N/A
  • AKBA N/A
  • Revenue
  • PWP $987,743,000.00
  • AKBA $184,909,000.00
  • Revenue This Year
  • PWP $5.79
  • AKBA $26.88
  • Revenue Next Year
  • PWP $18.31
  • AKBA $44.34
  • P/E Ratio
  • PWP N/A
  • AKBA N/A
  • Revenue Growth
  • PWP 59.48
  • AKBA N/A
  • 52 Week Low
  • PWP $14.12
  • AKBA $0.91
  • 52 Week High
  • PWP $27.03
  • AKBA $4.08
  • Technical
  • Relative Strength Index (RSI)
  • PWP 68.14
  • AKBA 58.46
  • Support Level
  • PWP $19.10
  • AKBA $3.48
  • Resistance Level
  • PWP $20.04
  • AKBA $3.75
  • Average True Range (ATR)
  • PWP 0.70
  • AKBA 0.17
  • MACD
  • PWP 0.20
  • AKBA -0.05
  • Stochastic Oscillator
  • PWP 84.59
  • AKBA 39.02

About PWP Perella Weinberg Partners

Perella Weinberg Partners is an independent advisory firm that provides strategic and financial advice to a wide range of clients. The Company's activities as an investment banking advisory firm constitute a single business segment that provides a range of advisory services, including advice related to strategic and financial decisions, mergers and acquisitions execution, shareholder and defense advisory, financing and capital solutions advice with resources focused on restructuring and liability management, capital markets advisory, private capital placement, as well as specialized underwriting and research services for the energy and related industries.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Share on Social Networks: